Real-world data, study design innovation, statistical methods, and evidence-generation approaches.
This week: a major proposed cut to NIH funding, FDA's broader shift toward flexible evidence standards, EMA's tailored biosimilar evidence model, a more practical read on how real-world data is actually being used in trials, and a reported Lilly-Insilico deal that keeps AI drug discovery firmly on the strategic agenda.